

## Central Zone

## Pathology and Laboratory Medicine Memorandum

| To:      | Provincial Oncology Group                                   |
|----------|---|
| From:    | Dr. Wenda Greer, Clinical Director of Molecular Diagnostics |
|          | Randy Veinotte, Esoteric Laboratory Manager                 |
| Date:    | December 18, 2020   |
| Subject: | Circulating Tumor DNA Testing                               |

The Molecular Diagnostics laboratory is now offering a new test, Circulating Tumor EGRF, to detect sensitizing (EGFR L858R and EGFR exon 19del) and resistance (EGFR T790M) EGFR mutations in circulating tumor DNA in lung cancer patients. The detection of these mutations in blood plasma might allow the patient to move to second line therapy without the need for a second biopsy at relapse.

To ensure appropriate utilization the requesting of this test will be restricted to oncologists.

The test must be ordered using the molecular requisition (Req #CD2573) and select "Circulating Tumor EGFR". Please include the patient's sensitizing EGFR mutation.

If you have any questions please contact Dr. Wenda Greer at 902-473-6691 (wenda.greer@nshealth.ca) or the Molecular Diagnostic laboratory at 902-473-6665.